A low dosage of aspirin could help to increase cancer patients’ survival chances by up to 20% and could also help stop their cancer from spreading, according to a new analysis.
A systematic review by researchers at the University of Cardiff, Wales, has led Professor Peter Elwood to call for randomised trials to establish the evidence needed to support low-dose aspirin as an effective additional treatment of cancer.
“There is a growing body of evidence that taking aspirin is of significant benefit in reducing some cancers,” said Professor Peter Elwood, who led the research, which is published in the latest edition of PLOS ONE.
“Whilst we know a low-dose of aspirin has been shown to reduce the incidence of cancer, its role in the treatment of cancer remains uncertain. As a result, we set out to conduct a systematic search of all the scientific literature.”
A team from the university’s School of Medicine reviewed the available scientific and looked at all of the available data, including five randomised trials and 42 observational studies of colorectal, breast and prostate cancers.
They found a significant reduction in mortality and cancer spread by patients who took a low-level dose of aspirin in addition to their cancer treatment.
Prof Elwood said their review suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a 15-20% reduction in deaths, plus a reduction in the spread of the cancer.
However, results from six studies of other cancers hinted at a reduction, but the numbers of patients were too few to enable confident interpretation.
They found mutation PIK3CA was present in about 20% of patients and seemed to be the reason why aspirin was associated with fewer colon cancer deaths.
The team also asked the study authors for further data on possible internal bleeding but no study reported serious or life-threatening bleeding.
Professor Elwood added: “While there is a desperate need for more detailed research to verify our review and to obtain evidence on less common cancers, we’d urge patients diagnosed with cancer to speak to their doctor about our findings so they can make an informed decision as to whether or not they should take a low-dose aspirin as part of their cancer treatment.”
As a result of the review, the team say their study highlights the need for randomised trials to establish the evidence needed to support low-dose aspirin as an effective additional treatment of cancer.
Elwood P, Morgan G, Pickering J et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLOS ONE. April 2016. [abstract]

Leave a Reply